FSGS: Pathogenesis and pathophysiology | With Dr Sanjeev Sethi

While focal segmental glomerulosclerosis (FSGS) is rare overall, it is one of the most common glomerular diseases on Europe, North America and Latin America. Rather than being a specific disease entity, it is a pattern of injury that takes various forms that, together with the clinical presentation, have important implications for treatment and prognosis. Join Dr Sanjeev Sethi, pathologist at the Mayo Clinic, Rochester, Minnesota, USA, for an overview of our current understanding of how FSGS develops and presents. By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.  References: 1. McGrogan A, Franssen CF, de Vries CS: The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. Nephrol Dial Transplant 26: 414–430, 2011  2. Sim JJ, Batech M, Hever A, Harrison TN, Avelar T, Kanter MH, Jacobsen SJ. Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population. Am J Kidney Dis. 2016 Oct;68(4):533-544.  3. Rosenberg AZ, Koop JB. Focal segmental glomerulosclerosis. Clin J Am SOc Nephrol. 2017;12(3): 502-517.   4. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276.   5. Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza F. Clinical and pathological phenotype of genetic casues of focal segmental glomerulosclerosis in adults. Clinical Kidney J. 2018;11 (2): 179-190.  Disclosures:  Dr Sanjeev Sethi has no relevant disclosures to report at this time. Funding:  This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME and validated by an independent steering committee; Travere Therapeutics has had no influence on the content of this education.